Disrupt the migraine market!

Compilenewborn

As the only drug approved by the US FDA to prevent and treat migraine at the same time, Biohaven Pharmaceuticals believes that its oral CGRP antagonist Nurtec ODT (rimegepant orally disintegrating tablet) has a very good market prospect

On Wednesday, Biohaven released a report stating that Nurtec ODT’s sales in the second quarter of this year reached $93 million, an increase of 112% from the previous quarter

This is the first quarterly report since Nurtec ODT was approved by the US FDA for the preventive treatment of migraine in May this year

Biohaven CEO Vlad Coric predicts that due to the approval of these two indications, Nurtec ODT will break the existing pattern of injectable antibody therapy, including Amgen Aimovig, Eli Lilly Emgality, Teva Ajovy, and Lingbei Vyepti

Earlier this year, Vlad Coric stated that if this option is available, patients may give up injectable drugs and receive oral CGRP therapy

Biohaven said on Wednesday that since the launch of Nurtec ODT last year, the company has counted more than 750,000 prescriptions so far, a 50% increase from April

The investment bank predicts that Nurtec ODT’s sales this year will reach 274 million U.

In contrast, Eli Lilly’s best-selling migraine Emgality had sales of $362 million last year.

But when talking about Eli Lilly’s challenge, Biohaven CEO Vlad Coric made no secrets, calling this a "competitive measure by a company with injections trying to protect market share

But what is certain is that Biohaven will eventually face competition with other oral therapies

Reference source: Biohaven set to be'a major migraine player' as Nurtec ODT sales dwarf estimates: analysts